06/01/23 8:30 AMNasdaq : YS clinical trialYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval From Philippines FDAYS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that its PIKA Rabies Vaccine was granted Phase 3 clinical trial approval from the...RHEA-AIneutral
05/18/23 8:25 AMNasdaq : YS conferencesYS Biopharma to Participate in the Virtual Benchmark Healthcare House Call Conference on May 23, 2023YS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced that it will participate in The Benchmark Company Healthcare House Call Virtual...RHEA-AIneutral
05/16/23 7:00 AMNasdaq : YS clinical trialYS Biopharma's PIKA Rabies Vaccine Receives Phase 3 Clinical Trial Approval in PakistanYS Biopharma Co., Ltd., a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing new generations of vaccines and therapeutic biologics for infectious diseases and cancer, today announced its PIKA Rabies Vaccine has received Phase 3 clinical trial approval from...RHEA-AIneutral
04/18/23 7:00 AMNasdaq : YS earningsYS Biopharma Announces Record Vaccine Revenues and Preliminary Financial Results for FY2023 Ended March 31, 2023YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and commercializing newRHEA-AIneutral
03/27/23 6:00 AMNasdaq : YS clinical trialcovid-19YS Biopharma's PIKA Recombinant COVID-19 Vaccine Demonstrates Superior Antibody Neutralization Responses Compared to Inactivated COVID-19 Vaccine in Phase II Head-to-Head Clinical StudyThe trial met its primary endpoint of superior immunogenicity of PIKA COVID-19 Vaccine vs inactivated COVID-19 vaccine, measured by GMT of neutralizing antibody against Omicron virus on Day 14, with statistical significance (95%CI: 2.1, 3.4, P<0.0001) based on interim data analysis The trial alsoRHEA-AIneutral
03/14/23 4:38 PMNasdaq : SMIH, YS, YSBPW low floatYS BIOPHARMA AND SUMMIT HEALTHCARE ANNOUNCE SHAREHOLDER APPROVAL OF BUSINESS COMBINATIONBusiness Combination to deliver approximately $36 million of gross proceeds YS Biopharma expects to close the Business Combination on March 16, 2023 YS Biopharma Ordinary Shares and YS Biopharma Warrants expected to begin trading on the Nasdaq on March 17, 2023 under the symbols "YS" and "YSBPW,"RHEA-AIpositive
